Leerink Partnrs Has Pessimistic View of Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB – Free Report) – Research analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for shares of Biogen in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings per share of $4.05 for the quarter, down from their prior […]

Leave a Reply

Your email address will not be published.

Previous post KeyCorp Research Analysts Lower Earnings Estimates for ESI
Next post FY2025 Earnings Forecast for ResMed Issued By Zacks Research